Johnny Kao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johnny Kao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Eric M. Genden
Department of Otolaryngology/Head and Neck Surgery, Mount Sinai School of Medicine, New York, New York
3 shared publicationsStuart Packer
Department of Medicine, Mount Sinai School of Medicine, New York, New York
3 shared publicationsAmir Lavaf
2 shared publicationsDelphine Huang
Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
2 shared publicationsHa Linh Vu
Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
2 shared publicationsJamie A. Cesaretti
Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
2 shared publications
Latest Publications
- 1 December 2009
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 9 (8) , 931-937
Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite some notable successes, less than 20% of patients respond to EGFR inhibition due to intrinsic and acquired resistance. Since EGFR inhibition is already used for lung, colorectal, breast and pancreas cancers in addition to HNSCC, overcoming treatment resistance would have a major impact on outcome. When the mechanisms of intrinsic resistance are identified, including mutations in the EGFR receptor, alternative therapeutic approaches should be employed. Mechanisms of acquired resistance that may be amenable to pharmacological therapies include dysregulation of EGFR degradation, constitutive activation of overlapping signal transduction pathways, especially cMET/HER3, the PI3K/Akt resistance pathway, angiogenesis and epithelial to mesenchymal transition. COX-2 is another promising target for HNSCC and preclinical data suggest that COX-2 inhibitors can affect most of the described acquired EGFR resistance pathways. Several combined EGFR and COX-2 inhibition trials have been completed and demonstrate promise for HNSCC. Combinatorial strategies of combined inhibition of EGFR and acquired resistance pathways in combination with radiation or chemotherapy are warranted.
- 1 December 2009
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 9 (8) , 931-937
Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite some notable successes, less than 20% of patients respond to EGFR inhibition due to intrinsic and acquired resistance. Since EGFR inhibition is already used for lung, colorectal, breast and pancreas cancers in addition to HNSCC, overcoming treatment resistance would have a major impact on outcome. When the mechanisms of intrinsic resistance are identified, including mutations in the EGFR receptor, alternative therapeutic approaches should be employed. Mechanisms of acquired resistance that may be amenable to pharmacological therapies include dysregulation of EGFR degradation, constitutive activation of overlapping signal transduction pathways, especially cMET/HER3, the PI3K/Akt resistance pathway, angiogenesis and epithelial to mesenchymal transition. COX-2 is another promising target for HNSCC and preclinical data suggest that COX-2 inhibitors can affect most of the described acquired EGFR resistance pathways. Several combined EGFR and COX-2 inhibition trials have been completed and demonstrate promise for HNSCC. Combinatorial strategies of combined inhibition of EGFR and acquired resistance pathways in combination with radiation or chemotherapy are warranted.
The diagnostic and prognostic utility of positron emission tomography/computed tomography‐based follow‐up after radiotherapy for head and neck cancer
BACKGROUND: The detection of subclinical head and neck cancer recurrence or a second primary tumor may improve survival. In the current study, the authors investigated the clinical value of a follow‐up program incorporating serial 18F‒fluorodeoxyglucose‒positron emission tomography integrated with computed tomography (PET/CT) in the detection of recurrent disease in patients with head and neck cancer.METHODS: A total of 240 PET/CT scans were reviewed in 80 patients with head and neck cancer who were treated with radiotherapy (RT) from July, 2005 through August, 2007. All patients were followed with clinical examination, PET/CT, and correlative imaging for a minimum of 11 months (median follow‒up, 21 months).RESULTS: The sensitivity, specificity, and positive and negative predictive values of PET/CT‐based follow‐up for detecting locoregional recurrence were 92%, 82%, 42%, and 98%, respectively. Corresponding values for distant metastases or second primary tumors were 93%, 96%, 81%, and 98%, respectively. Eight patients (10%) developed disease recurrences or second primary tumors that were amenable to salvage surgery with negative surgical margins. The 2‐year progression‐free survival and 2‐year overall survival rates were significantly different between patients who had a negative and those with a positive PET/CT result within 6 months of the completion of RT (93% vs 30% [P<.001] and 100% vs 32% [P<.001], respectively).CONCLUSIONS: Although post‐therapy follow‐up using PET/CT is reportedly associated with a high false‐positive rate in the irradiated head and neck, PET/CT appears to be a highly sensitive technique for the detection of recurrent disease. Furthermore, negative PET/CT results within 6 months of the completion of RT offer significant prognostic value. Cancer 2009. © 2009 American Cancer Society.
The diagnostic and prognostic utility of positron emission tomography/computed tomography‐based follow‐up after radiotherapy for head and neck cancer
BACKGROUND: The detection of subclinical head and neck cancer recurrence or a second primary tumor may improve survival. In the current study, the authors investigated the clinical value of a follow‐up program incorporating serial 18F‒fluorodeoxyglucose‒positron emission tomography integrated with computed tomography (PET/CT) in the detection of recurrent disease in patients with head and neck cancer.METHODS: A total of 240 PET/CT scans were reviewed in 80 patients with head and neck cancer who were treated with radiotherapy (RT) from July, 2005 through August, 2007. All patients were followed with clinical examination, PET/CT, and correlative imaging for a minimum of 11 months (median follow‒up, 21 months).RESULTS: The sensitivity, specificity, and positive and negative predictive values of PET/CT‐based follow‐up for detecting locoregional recurrence were 92%, 82%, 42%, and 98%, respectively. Corresponding values for distant metastases or second primary tumors were 93%, 96%, 81%, and 98%, respectively. Eight patients (10%) developed disease recurrences or second primary tumors that were amenable to salvage surgery with negative surgical margins. The 2‐year progression‐free survival and 2‐year overall survival rates were significantly different between patients who had a negative and those with a positive PET/CT result within 6 months of the completion of RT (93% vs 30% [P<.001] and 100% vs 32% [P<.001], respectively).CONCLUSIONS: Although post‐therapy follow‐up using PET/CT is reportedly associated with a high false‐positive rate in the irradiated head and neck, PET/CT appears to be a highly sensitive technique for the detection of recurrent disease. Furthermore, negative PET/CT results within 6 months of the completion of RT offer significant prognostic value. Cancer 2009. © 2009 American Cancer Society.
- Open Access
Phase 1 study of concurrent sunitinib and image‐guided radiotherapy followed by maintenance sunitinib for patients with oligometastases
BACKGROUND: To determine the safety and maximum‐tolerated dose of concurrent sunitinib and image‐guided radiotherapy (IGRT) followed by maintenance sunitinib in oligometastastic patients.METHODS: Eligible patients had 1 to 5 sites of metastatic cancer measuring ≤6 cm. The most common treatment sites were bone, liver, and lung. Patients were treated with concurrent sunitinib (Day 1 through Day 28) and IGRT (40‐50 Gy in 10 fractions starting on Day 8) followed by maintenance sunitinib (50 mg daily, 4 weeks on/2 weeks off starting on Day 43). The starting dose was sunitinib 25 mg and IGRT 40 Gy. Doses were escalated in a ping‐pong design with incremental increases in either sunitinib or IGRT.RESULTS: Twenty‐one patients with 36 metastatic lesions were enrolled, with a median follow‐up of 10 months. No dose limiting toxicities (DLT) were noted at dose levels 1 or 2 (SU 37.5 mg/RT 40 Gy). One of 10 patients at dose level 3 (SU 37.5 mg/RT 50 Gy) and 2 of 5 patients at dose level 4 (SU 50 mg/RT 50 Gy) experienced DLTs comprising grade 4 myelosuppression and grade 3 nausea. At last follow‐up, 8 patients are alive without evidence of progression. The 1‐year local, progression‐free, and overall survival were 85%, 44%, and 75%, respectively.CONCLUSIONS: Addition of SU (25 to 37.5 mg) to IGRT is tolerable in patients with oligometastases, without potentiation of RT toxicity. On the basis of promising antitumor responses observed with this novel combination, a multi‐institutional phase 2 trial using SU 37.5 mg/RT 50 Gy is ongoing. Cancer 2009; 115:3571–80. © 2009 American Cancer Society.
Open AccessPhase 1 study of concurrent sunitinib and image‐guided radiotherapy followed by maintenance sunitinib for patients with oligometastases
BACKGROUND: To determine the safety and maximum‐tolerated dose of concurrent sunitinib and image‐guided radiotherapy (IGRT) followed by maintenance sunitinib in oligometastastic patients.METHODS: Eligible patients had 1 to 5 sites of metastatic cancer measuring ≤6 cm. The most common treatment sites were bone, liver, and lung. Patients were treated with concurrent sunitinib (Day 1 through Day 28) and IGRT (40‐50 Gy in 10 fractions starting on Day 8) followed by maintenance sunitinib (50 mg daily, 4 weeks on/2 weeks off starting on Day 43). The starting dose was sunitinib 25 mg and IGRT 40 Gy. Doses were escalated in a ping‐pong design with incremental increases in either sunitinib or IGRT.RESULTS: Twenty‐one patients with 36 metastatic lesions were enrolled, with a median follow‐up of 10 months. No dose limiting toxicities (DLT) were noted at dose levels 1 or 2 (SU 37.5 mg/RT 40 Gy). One of 10 patients at dose level 3 (SU 37.5 mg/RT 50 Gy) and 2 of 5 patients at dose level 4 (SU 50 mg/RT 50 Gy) experienced DLTs comprising grade 4 myelosuppression and grade 3 nausea. At last follow‐up, 8 patients are alive without evidence of progression. The 1‐year local, progression‐free, and overall survival were 85%, 44%, and 75%, respectively.CONCLUSIONS: Addition of SU (25 to 37.5 mg) to IGRT is tolerable in patients with oligometastases, without potentiation of RT toxicity. On the basis of promising antitumor responses observed with this novel combination, a multi‐institutional phase 2 trial using SU 37.5 mg/RT 50 Gy is ongoing. Cancer 2009; 115:3571–80. © 2009 American Cancer Society.
Adjuvant radiotherapy improves overall survival for patients with lymph node‐positive head and neck squamous cell carcinoma
BACKGROUND.: Although adjuvant radiotherapy (RT) is often recommended for locally advanced squamous cell carcinoma of the head and neck (HNSCC), its effect on overall or cancer‐specific survival has not been clearly demonstrated. In the current study, the frequency and effect of adjuvant RT on overall survival was investigated in patients with resected lymph node‐positive head and neck cancer.METHODS.: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients were selected with lymph node‐positive HNSCC (American Joint Committee on Cancer and SEER stage 3/4) who were treated either with surgery alone or surgery and RT and were diagnosed between 1988 and 2001. A total of 8795 patients who met the inclusion criteria for analysis comprised the study population, with a median follow‐up of 4.3 years for patients still alive at the time of last follow‒up.RESULTS.: Adjuvant RT was utilized in 84% of patients. Adjuvant RT improved the 5‐year overall survival (43.2% [95% confidence interval (95% CI), 41.9–44.4%] for surgery + RT vs 33.4% [95% CI, 30.7–36.0%] for surgery alone; P < .001) and cancer‐specific survival (50.9% for surgery + RT vs 42.1% for surgery) on univariate analysis. On multivariate analysis, adjuvant RT (hazards ratio [HR] of 0.78; 95% CI, 0.71–0.86 [P < .001]) remained a significant predictor of improved survival. The significant benefit of radiation on overall survival was noted for lymph node‐positive patients with both primary tumors localized to the involved organ (HR of 0.81; 95% CI, 0.71–0.94 [P = .007]) and more locally invasive primary tumors (HR of 0.77; 95% CI, 0.68–0.87 [P < .001]).CONCLUSIONS.: In what to the authors' knowledge is the largest reported analysis of adjuvant RT in patients with locally advanced HNSCC published to date, adjuvant RT resulted in an approximately 10% absolute increase in 5‐year cancer‐specific survival and overall survival for patients with lymph node‐positive HNSCC compared with surgery alone. Despite combined surgery and adjuvant RT, outcomes in this high‐risk population remain suboptimal, emphasizing the need for continued investigation of innovative treatment approaches. Cancer 2008. © 2007 American Cancer Society.
Adjuvant radiotherapy improves overall survival for patients with lymph node‐positive head and neck squamous cell carcinoma
BACKGROUND.: Although adjuvant radiotherapy (RT) is often recommended for locally advanced squamous cell carcinoma of the head and neck (HNSCC), its effect on overall or cancer‐specific survival has not been clearly demonstrated. In the current study, the frequency and effect of adjuvant RT on overall survival was investigated in patients with resected lymph node‐positive head and neck cancer.METHODS.: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients were selected with lymph node‐positive HNSCC (American Joint Committee on Cancer and SEER stage 3/4) who were treated either with surgery alone or surgery and RT and were diagnosed between 1988 and 2001. A total of 8795 patients who met the inclusion criteria for analysis comprised the study population, with a median follow‐up of 4.3 years for patients still alive at the time of last follow‒up.RESULTS.: Adjuvant RT was utilized in 84% of patients. Adjuvant RT improved the 5‐year overall survival (43.2% [95% confidence interval (95% CI), 41.9–44.4%] for surgery + RT vs 33.4% [95% CI, 30.7–36.0%] for surgery alone; P < .001) and cancer‐specific survival (50.9% for surgery + RT vs 42.1% for surgery) on univariate analysis. On multivariate analysis, adjuvant RT (hazards ratio [HR] of 0.78; 95% CI, 0.71–0.86 [P < .001]) remained a significant predictor of improved survival. The significant benefit of radiation on overall survival was noted for lymph node‐positive patients with both primary tumors localized to the involved organ (HR of 0.81; 95% CI, 0.71–0.94 [P = .007]) and more locally invasive primary tumors (HR of 0.77; 95% CI, 0.68–0.87 [P < .001]).CONCLUSIONS.: In what to the authors' knowledge is the largest reported analysis of adjuvant RT in patients with locally advanced HNSCC published to date, adjuvant RT resulted in an approximately 10% absolute increase in 5‐year cancer‐specific survival and overall survival for patients with lymph node‐positive HNSCC compared with surgery alone. Despite combined surgery and adjuvant RT, outcomes in this high‐risk population remain suboptimal, emphasizing the need for continued investigation of innovative treatment approaches. Cancer 2008. © 2007 American Cancer Society.